PredOmix Technologies Pvt. Ltd. Company Profile

Background

PredOmix Technologies Pvt. Ltd., established in 2018 and headquartered in Gurugram, Haryana, India, is an innovation-driven health tech company specializing in early-stage cancer detection. The company's mission is to develop innovative solutions for cancer detection, aiming to revolutionize the field by addressing pressing scientific challenges through cutting-edge research and technology. PredOmix integrates multi-dimensional approaches and leverages deep learning to pioneer technologies in preventive healthcare and early-stage disease diagnosis.

Key Strategic Focus

PredOmix's strategic focus centers on the development of non-invasive, early cancer detection methods. The company specializes in integrating metabolomics—the comprehensive study of metabolites—and artificial intelligence to identify cancer-specific metabolic signatures. This approach enables the detection of multiple cancers at early stages, thereby improving treatment outcomes and patient survival rates. PredOmix targets both high-risk and asymptomatic populations, aiming to make early cancer detection accessible and routine.

Financials and Funding

As of the latest available data, PredOmix Technologies Pvt. Ltd. has an authorized capital of ₹1.00 million and a paid-up capital of ₹0.14 million. The company has experienced significant financial growth, with a 132.6% increase in net worth and a 91.73% rise in profit for the fiscal year ending March 31, 2024. PredOmix has participated in accelerator/incubator programs, notably with Startup Haryana, which has provided support in its developmental stages.

Pipeline Development

PredOmix's flagship product, OncoVeryx-F, is a groundbreaking blood test capable of detecting early-stage cancers in women with 98% accuracy. This test can identify the presence or absence of cancer and accurately determine the tissue of origin in a single test. OncoVeryx-F offers a comprehensive screening solution for cancers such as breast, endometrial, cervical, and ovarian cancers. The company has also developed a similar test for men, capable of detecting approximately 32 types of cancer with similar accuracy.

Technological Platform and Innovation

PredOmix distinguishes itself through its proprietary integration of metabolomics and deep learning technologies. By analyzing patterns of metabolites in blood samples, the company identifies cancer-specific metabolic signatures. This innovative approach allows for the detection of multiple cancers in their early stages, enhancing the potential for successful treatment. The company's AI-driven methodologies enable the deconvolution of complex metabolomic data, facilitating precise and sensitive cancer detection.

Leadership Team

Radhakrishna S. Hemmad: Chief Executive Officer (CEO) of PredOmix Health Sciences Pte. Ltd., with over two decades of experience in pharmaceuticals and consumer health across the APAC region.

Dr. Kanury V S Rao: Co-Founder and Chief Scientific Officer (CSO), a renowned expert in immunology and molecular biology with over 25 years at the International Centre for Genetic Engineering and Biotechnology (ICGEB).

Dr. Najmuddin Saquib: Head of Metabolomics Research, holding a Ph.D. in System Biology, with extensive experience in mass spectrometry-based metabolomics.

Dr. Ankur Gupta: Head of Data Analytics, with a strong background in mathematics, AI, and machine learning, leading a team of AI experts in disease diagnostics and drug discovery.

Pradeep Kumar: Senior Administrative Manager, with over five years of experience managing research laboratories in reputed scientific institutions.

Dr. Shweta Grewal: Head of Marketing & Business Development, with over 15 years in strategic planning, marketing, and corporate communications, holding a Ph.D. in Molecular Biology.

Tikshika Good: Managing Director of PredOmix Health Sciences LLC (USA), with a blend of healthcare and marketing expertise, overseeing high-impact initiatives.

Dr. Gulshan Yadav: Consultant Pathologist, with extensive experience in pathology, including microbiology, serology, and histopathology.

Ashish Rana: Chief Financial Officer (CFO), a Fellow Member of the Institute of Chartered Accountants of India with 15 years of professional experience.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within PredOmix's leadership team.

Competitor Profile

Market Insights and Dynamics

The global cancer diagnostics market is experiencing significant growth, driven by increasing cancer prevalence and advancements in diagnostic technologies. Early detection remains a critical factor in improving treatment outcomes, positioning companies like PredOmix at the forefront of this expanding market.

Competitor Analysis

PredOmix operates in a competitive landscape alongside companies such as Grail, Guardant Health, and Thrive Earlier Detection, all focusing on early cancer detection through liquid biopsy and AI-driven diagnostics. These competitors emphasize non-invasive testing methods and have made notable advancements in multi-cancer detection capabilities.

Strategic Collaborations and Partnerships

PredOmix has established significant collaborations to enhance its market position and innovation capacity. Notably, the company partnered with CŌRE Diagnostics to launch OncoVeryx-F, aiming to provide a highly accurate, non-invasive screening tool for early cancer detection in women. This collaboration combines PredOmix's technological expertise with CŌRE Diagnostics' market reach and clinical capabilities.

Operational Insights

PredOmix's strategic considerations include differentiating itself through its unique integration of metabolomics and AI, offering a non-invasive, highly accurate cancer detection method. The company's focus on early detection positions it advantageously in the market, addressing a critical need for improved diagnostic tools. Collaborations with clinical institutions and research organizations further strengthen its capabilities and market reach.

Strategic Opportunities and Future Directions

PredOmix aims to expand its product portfolio to include early detection tests for a broader range of cancers and to target both high-risk and asymptomatic populations. The company is also exploring international markets to extend the reach of its innovative diagnostic solutions. Continued investment in research and development, along with strategic partnerships, will be key to sustaining its growth and impact in the field of cancer diagnostics.